Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
https://doi.org/10.21518/2079-701X-2019-19-92-102
Abstract
Introduction. Colorectal cancer (CRC) holds leading positions in the cancer incidence and mortality patterns worldwide. In this regard, the study of new effective drugs and development of new treatment regimens for advanced CRC is receiving priority attention today.
Objective of the study: develop a new 3-component chemotherapy (CT) regimen based on the combination of oxaliplatin (oxa)/irinotecan (iri)/tegafur (Ftorafur®) ± Leucovorin, study its efficacy and safety in the first-line therapy for advanced CRC; assess the feasibility of its use in the outpatient setting.
Materials and methods. The study included patients with advanced CRC, who had not previously received drug therapy for disseminated disease. In this study, all patients received first-line CT therapy based on a combination of: oxa/iri/tegafur (Ftorafur®) ± Leucovorin. The researchers developed and studied 2 CT regimens. CT regimen in subgroup I: iri (150 mg/m2 BSA intravenous (IV) infusion, 90-minute infusion, Day 1) + oxa (100 mg/m2 BSA IV infusion, 2-hour infusion, Day 1) + tegafur (Ftorafur ®) (1200 mg (400 mg TID), per os, daily, Days 1–14) + Leucovorin 50 mg TID, 15–20 minutes before taking tegafur, daily, Days 1–14. The next course starts from Day 22. CT regimen in subgroup II: iri (150 mg/m2 BSA intravenous (IV) infusion, 90-minute infusion, Days 1 and 15) + oxa (100 mg/m2 BSA IV infusion, 2-hour infusion, Days 1 and 15) + tegafur (Ftorafur®) (1200 mg (400 mg TID), per os, daily, Days 1–14). The interval between the courses is 14 days. The next course starts from Day 29. The researchers assessed the immediate and long-term results of treatment and safety of two above-mentioned first-line therapy chemotherapy regimens for advanced CRC.
Results. The study included 30 patients with advanced CRC, 6 of whom received 3-week СТ regimen (subgroup I), 24 patients received 2-week regimen (subgroup II). In subgroup I, 4 (66.7%) patients achieved partial regression (PR) of metastases, 2 (33.3%) patients achieved long-term stable disease (SD ≥ 6 months). Thus, the disease control (PR + SD ≥6 months) was achieved in 100% of cases. The median progression-free survival (PFS) in this subgroup was 9.53 months; the median overall survival (OS) was 13.60 months. In subgroup II, PR was reported in 13/23 (56.5%) patients, of which 4 (17.4%) were radically operated. SD ≥6 months was achieved in 6 (26.1%) patients. Thus, the disease control (PR + SD ≥6 months) was achieved in 82.6% of cases. The median progression-free survival (PFS) in this subgroup was 8.73 months; the median overall survival (OS) was 17.24 months. In the general group of patients, who received therapy regimens I and II, the disease control was 86.2% (PR-58.6%; SD ≥6 months was 27.6%); median PFS was 9.57 months; median OS was 16.8 months. Conclusions. Data resulting from our study suggest that the combination of oxa, iri, and tegafur (Ftorafur®) ± Leucovorin is effective and safe 3-component first-line CT regimen for advanced CRC, which is easy for use in outpatient setting.
Objective of the study: develop a new 3-component chemotherapy (CT) regimen based on the combination of oxaliplatin (oxa)/irinotecan (iri)/tegafur (Ftorafur®) ± Leucovorin, study its efficacy and safety in the first-line therapy for advanced CRC; assess the feasibility of its use in the outpatient setting.
Materials and methods. The study included patients with advanced CRC, who had not previously received drug therapy for disseminated disease. In this study, all patients received first-line CT therapy based on a combination of: oxa/iri/tegafur (Ftorafur®) ± Leucovorin. The researchers developed and studied 2 CT regimens. CT regimen in subgroup I: iri (150 mg/m2 BSA intravenous (IV) infusion, 90-minute infusion, Day 1) + oxa (100 mg/m2 BSA IV infusion, 2-hour infusion, Day 1) + tegafur (Ftorafur ®) (1200 mg (400 mg TID), per os, daily, Days 1–14) + Leucovorin 50 mg TID, 15–20 minutes before taking tegafur, daily, Days 1–14. The next course starts from Day 22. CT regimen in subgroup II: iri (150 mg/m2 BSA intravenous (IV) infusion, 90-minute infusion, Days 1 and 15) + oxa (100 mg/m2 BSA IV infusion, 2-hour infusion, Days 1 and 15) + tegafur (Ftorafur®) (1200 mg (400 mg TID), per os, daily, Days 1–14). The interval between the courses is 14 days. The next course starts from Day 29. The researchers assessed the immediate and long-term results of treatment and safety of two above-mentioned first-line therapy chemotherapy regimens for advanced CRC.
Results. The study included 30 patients with advanced CRC, 6 of whom received 3-week СТ regimen (subgroup I), 24 patients received 2-week regimen (subgroup II). In subgroup I, 4 (66.7%) patients achieved partial regression (PR) of metastases, 2 (33.3%) patients achieved long-term stable disease (SD ≥ 6 months). Thus, the disease control (PR + SD ≥6 months) was achieved in 100% of cases. The median progression-free survival (PFS) in this subgroup was 9.53 months; the median overall survival (OS) was 13.60 months. In subgroup II, PR was reported in 13/23 (56.5%) patients, of which 4 (17.4%) were radically operated. SD ≥6 months was achieved in 6 (26.1%) patients. Thus, the disease control (PR + SD ≥6 months) was achieved in 82.6% of cases. The median progression-free survival (PFS) in this subgroup was 8.73 months; the median overall survival (OS) was 17.24 months. In the general group of patients, who received therapy regimens I and II, the disease control was 86.2% (PR-58.6%; SD ≥6 months was 27.6%); median PFS was 9.57 months; median OS was 16.8 months. Conclusions. Data resulting from our study suggest that the combination of oxa, iri, and tegafur (Ftorafur®) ± Leucovorin is effective and safe 3-component first-line CT regimen for advanced CRC, which is easy for use in outpatient setting.
About the Authors
N. V. Dobrova
Research Institute of Clinical Oncology, Federal State Budgetary Institution «N.N.Blokhin Russian Cancer Research Centre» of the Ministry of Health of Russian Federation
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Cancer Drug Therapy (Chemotherapeutic) Department No 3
24, Kashirskoye sh., 115478, Moscow, Russia
A. D. Darenskaya
Research Institute of Clinical Oncology, Federal State Budgetary Institution «N.N.Blokhin Russian Cancer Research Centre» of the Ministry of Health of Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Cancer Drug Therapy (Chemotherapeutic) Department No 3
24, Kashirskoye sh., 115478, Moscow, Russia
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Cancer Drug Therapy (Chemotherapeutic) Department No 3
24, Kashirskoye sh., 115478, Moscow, Russia
References
1. Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds.). Malignant neoplasms in Russia in 2013 (morbidity and mortality). Moscow: P. A. Gertsen MROI branch of the FSBI «NMIRTS» of the Ministry of Health of the Russian Federation; 2015. 250 c. (In Russ.) Available at: https://nmicr.ru/upload/doc/2017/170914_zno_v_2015.pdf.
2. Manzyuk L.V., Perevodchikova N.I., Gorbunova V.A. et al. Ftorafur: the first oral ftorpirimidinam in the treatment of metastatic colorectal cancer. Sovremennaya onkologiya = Current Oncology. 2001;3(4):32–34. (In Russ.)
3. Semenov N.N. Combined treatment of liver metastases of colorectal cancer. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2002;(24):1109–1111. (In Russ.) Available at: https://www.rmj.ru/archive/onkologiya_5/.
4. Tjulandin S.A., Tryakin A.A., Fedyanin M.Yu. Chemotherapy in patients with advanced colon cancer. Sovremennaya onkologiya = Current Oncology. 2010;(2):18–24. (In Russ.) Available at: https://con-med.ru/magazines/contemporary/contemporary-02-2010/khimioterapiya_bolnykh_rasprostranennym_rakom_tolstoy_kishki/.
5. Gorbunova V.A., Orel N.F., Besova N.S. Recent advances in clinical chemotherapy of malignant tumors. Rossiyskiy bioterapevticheskiy zhurnal = Russian Biotherapeutic Journal. 2003;2:15–26. (In Russ.)
6. Dobrova N.V. Combination of tegafur (ftorafur), leucovorin and oxaliplatin (TELVOX): a new effective regimen for first-line treatment of colorectal cancer metastases. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2011;1:18–24. (In Russ.) Available at: https://www.rmj.ru/articles/onkologiya/Kombinaciya_Tegafura_Ftorafur_Leykovorina_i_Oksaliplatina_TELVOX__novyy_effektivnyy_reghim_I_linii_himioterapii_pri_metastazah_kolorektalynogo_raka/.
7. Lichinitser M.R., Semenov N.N. New horizons for oxaliplatin (eloxatine). Farmateka = Pharmateca. 2004;(18):21–5. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/5833.
8. Lichinitser M.R. Oxaliplatin (eloxatin): new treatment options for cancer and lymphoma patients. Mezhdunarodnyy zhurnal meditsinskoy praktiki = International Journal of Medical Practice. 2001;(2):69–72. (In Russ.)
9. Lichinitser M.R. Oxaliplatin (eloxatin): new treatment options for cancer and lymphoma patients. Provizor = Pharmaceutist. 2001;(19):39–41. (In Russ.) Available at: http://provisor.com.ua/archive/2001/N19/art_39.php.
10. Semenov N.N. Activity of oxaliplatin (eloxatin) in platinum-sensitive tumors. Farmateka = Pharmateca. 2005;(18):63–65. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/6343.
11. Zhukova L.G., Lichinitser M.R., Semenov N.N. et al. Efficacy and safety of a combination of iriten(irinotecan) + fluorouracil + leucovorin in the first-line treatment of metastatic colorectal cancer. Farmateka = Pharmateca 2007;(18):84–86. Available at: https://pharmateca.ru/ru/archive/article/7019.
12. Gutorov S.L. Irinotecan in the treatment of colon cancer. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2005;(13):884–7. (In Russ.) Available at: https://www.rmj.ru/articles/obshchie-stati/Irinotekan_v_lechenii_raka_tolstoy_kishki/.
13. Dobrova N.V. Xeloda in the treatment of metastatic colorectal cancer. Farmateka Pharmateca 2010; (17):44–50. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/7975.
14. Dobrova N.V. Xeloda in the treatment of patients with metastatic colorectal cancer. Onkologiya = Oncology. 2011;(1):41–45. (In Russ.)
15. Lichinitser M.R., Semenov N.N., Paschenko N.V. Capecitabine (xeloda) in the treatment of colorectal and breast cancers: new opportunities. Farmateka = Pharmateca. 2002;(12):17–20. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/5680.
16. Fedyanin M. Yu., Tryakin A. A. Capecitabine and fluorouracil in the treatment of colorectal and gastric cancers: analysis of direct comparison studies. Farmateka = Pharmateca. 2011;(17):20–26. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/8228.
17. [Fedyanin M. Yu.,Tryakin A. A. Capecitabine and fluorouracil in the treatment of colorectal and gastric cancers: analysis of direct comparison studies. Klinicheskaya onkologiya = Clinical Oncology. 2012;1:115–118. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/8228.
18. Chau I., Cunningham D. Treatment in advanced colorectal cancer: what when and how? Br J Cancer. 2009;100(11):1704–1719. doi: 10.1038/sj.bjc.6605061.
19. Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–237. doi: 10.1200/JCO.2004.05.113.
20. Masi G., Loupakis F., Pollina L. et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin,oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–425. doi: 10.1097/SLA.0b013e31819a0486.
21. Vasile E., Masi G., Fornaro L. et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer. 2009;100(11):1720–4. doi: 10.1038/sj.bjc.6605075.
22. Ychou M., Viret F., Kramar A. et al. Tritherapy with fluorouracil/leucovorin irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth Pharmacol. 2008;62(2):195–201. Available at: https://link.springer.com/article/10.1007%2Fs00280-007-0588-3.
23. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J ClinOncol. 2004;22:1209–1214. doi: 10.1200/JCO.2004.11.037.
24. Darenskaya A.D., Dobrova N.V. Triple combination of irinotecan + oxaliplatin + 5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer: first experience with a new treatment regimen. Onkologicheskaya koloproktologiya = Colorectal oncology. 2018;1:50–66. (In Russ.) doi: https://doi.org/10.17650/2220-3478-2018-8-1-50-66.
25. Darenskaya A.D., Dobrova N.V. New regimen of first-line chemotherapy for metastatic colorectal cancer. Farmateka = Pharmateca. 2014;8:57–61. (In Russ.)
26. Darenskaya A., Dobrova N.V., Lichinitser M.R. Oxaliplatin, irinotecan, and fluorouracil in the prolonged regimen for the first-line therapy of metastatic colorectal cancer: New therapy regimen. J Clin Oncol. 2015;33(Suppl):e14617.
27. Darenskaya A.D., Dobrova N.V., Zhukova L.G. et al. Successful treatment of metastatic colorectal cancer with achieving complete pathological response (first-line chemotherapy): a case report. Farmateka = Pharmateca. 2016;8:93–99. (In Russ.)
28. Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–1676. doi: 10.1200/JCO.2006.09.0928.
29. Gruenberger T., Bridgewater J. A., Chau I. et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA. J Clin Oncol. 2013;31(Suppl 15):3619. doi: 10.1200/jco.2013.31.15_suppl.3619.
30. Vakhabova Yu.V., Dobrova N.V., Lichinitser M.R. Combination of tomudex (raltitrexed) and ftorafur (tegafur): a new effective chemotherapy regimen for colorectal cancer metastases. In: Chissov V.I., Davydov M.I. (eds.). Oncology: national guidelines. Moscow: GEOTAR-Media; 2008:705–710. (In Russ.)
31. Dobrova N. V., Vakhabova Yu. V., Lichinitser M. R. First-line chemotherapy for colorectal cancer metastases: tomudex and ftorafur. Meditsinskiy vestnik = Medical Bulletin. 2008;35(462):22–23. (In Russ.)
32. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. doi: 10.1093/jnci/92.3.205.
33. Kim S.Y., Hong Y.S., Shim E.K., Kong S.-Y., Shin A., Baek J.Y., Jung K.H. . S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. Br J Cancer. 2013;109(6):1420–1427. doi: 10.1038/bjc.2013.479.
34. Van Cutsem E., Lang I., Folprecht G. et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. J Clin Oncol. 2010. Gastrointestinal Cancers Symposium;281(abstr.):4000. Available at: https://slideplayer.com/slide/9261952/.
35. Bokemeyer C., Bondarenko I., Makhson A. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671. doi: 10.1200/JCO.2008.20.8397.
Review
For citations:
Dobrova NV, Darenskaya AD. Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer. Meditsinskiy sovet = Medical Council. 2019;(19):92-102. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-92-102
Views:
589
Email this article 